Form 4: Elanco EVP Granted Equity, Reports Tax Withholding

Elanco Animal Health's Executive Vice President, Ellen de Brabander, reported new equity grants and a disposition of shares for tax purposes.

Summary

• Ellen de Brabander, Executive Vice President of Research, Development and Regulatory Affairs at Elanco Animal Health Inc., reported several transactions on March 1, 2026.
• Acquired 67,564 shares of common stock at a price of $0, increasing beneficial ownership to 289,304 shares.
• Disposed of 46,278 shares of common stock at $26.4 per share, likely for tax withholding purposes, reducing beneficial ownership to 243,026 shares.
• Received a grant of 25,360 restricted stock units (RSUs) at $0, increasing beneficial ownership to 268,386 shares. These RSUs vest in three equal annual installments starting March 1, 2027.
• Received a grant of 51,819 employee stock options with an exercise price of $26.4. These options also vest in three equal annual installments starting March 1, 2027, and expire on March 1, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it reflects ongoing executive compensation and retention strategies through equity grants, aligning management interests with long-term company performance. The tax-related disposition is a routine event.

Positives

• Grant of 25,360 restricted stock units (RSUs) to a key executive, aligning management's interests with shareholders.
• Grant of 51,819 employee stock options with an exercise price of $26.4, providing long-term incentive.
• The grants demonstrate continued commitment to executive compensation tied to future performance.

Negatives

• Disposition of 46,278 shares of common stock for tax withholding purposes, which represents a reduction in direct beneficial ownership.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend through March 1, 2029, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that equity grants to senior executives are a standard practice in the animal health industry, aiming to align executive incentives with long-term shareholder value creation. Such grants are common for retaining key talent in competitive sectors.

Comparison to Industry Standards

• Equity compensation packages, including restricted stock units and stock options with multi-year vesting schedules, are standard practice across the pharmaceutical and animal health sectors.
• Companies like Zoetis Inc. and IDEXX Laboratories Inc. frequently utilize similar long-term incentive plans for their executives to foster retention and performance alignment.
• The specific grant sizes are commensurate with an Executive Vice President role in a company of Elanco's scale.

Related Party Transactions

• The reported transactions involve equity grants and dispositions between Elanco Animal Health Inc. and its Executive Vice President, Ellen de Brabander, which are considered related party transactions in the context of executive compensation.

Stakeholder Impact

• Shareholders: The equity grants align the executive's long-term interests with shareholder value creation. The disposition for tax purposes is a routine event and does not indicate a lack of confidence.
• Employees: Standard executive compensation practices can positively influence overall employee morale and retention strategies.

Next Steps

• Vesting of restricted stock units: one-third on March 1, 2027, one-third on March 1, 2028, and the remaining on March 1, 2029.
• Vesting of stock options: one-third on March 1, 2027, one-third on March 1, 2028, and the remaining on March 1, 2029.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, specifically equity grants and a tax-related share disposition. While these grants align executive interests with long-term shareholder value, they do not present new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive corporate updates.

Keywords

Elanco Animal Health, ELAN, Ellen de Brabander, SEC Form 4, Insider Trading, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Tax Withholding